Elicit: Real-Time Kidney Damage Markers (public)
What are the most effective real-time markers of kidney cell damage?
NGAL, [TIMP‑2]·[IGFBP7], and KIM-1 are the most effective real-time markers of kidney cell damage, showing high diagnostic accuracy when measured at appropriate time windows and achieving superior performance when combined in multi-marker panels.
Abstract
Real‐time markers for kidney cell damage most consistently report high diagnostic accuracy when measured in the appropriate clinical context and time window. Urinary neutrophil gelatinase‐associated lipocalin (NGAL) rises within 2–6 hours after injury, with studies reporting area under the curve (AUC) values up to 0.91, sensitivities of 84–100%, and specificities as high as 99.5%. Urinary [TIMP‑2]·[IGFBP7] is typically measured at 6–12 hours post‐injury and shows AUC values ranging from 0.70 to 0.94, with reported sensitivities of 42–96% and specificities up to 95%. Urinary kidney injury molecule‑1 (KIM‑1) measured at 12–24 hours post‐insult yields moderate performance (AUC 0.66–0.84) with sensitivities between 75.9% and 91.6% and specificities up to 95.2%.
When combined in multi‐marker panels, these biomarkers often achieve superior performance. For example, panels including NGAL, [TIMP‑2]·[IGFBP7], and cystatin C have produced AUC values as high as 0.98, while combinations with additional markers have reached similar levels of discrimination. These findings, drawn from a diverse set of populations and clinical settings—ranging from cardiac surgery and intensive care to emergency presentations—support the use of NGAL, [TIMP‑2]·[IGFBP7], and KIM‑1 as effective real‐time indicators of kidney cell damage.
Methods
We analyzed 40 sources from an initial pool of 999, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question. More on methods
Results
Characteristics of Included Studies
| Study | Study Population | Biomarkers Evaluated | AKI Definition | Primary Outcome |
|---|---|---|---|---|
| Bihorac et al., 2014 | Critically ill patients (n=420) | Urinary [TIMP-2]·[IGFBP7] | No mention found | Prediction of moderate to severe AKI (12h) |
| Piedrafita et al., 2022 | Cardiac surgery (n=1170), ICU (n=1569) | Urinary peptide signature, NGAL, calprotectin, [TIMP-2]/[IGFBP7] | KDIGO 2012 | Early AKI prediction (7-day) |
| Sun et al., 2024 | Critically ill patients (n=581) | 12 urinary biomarkers, U-AKIpredTM (alpha-1-microglobulin, L-FABP, IGFBP7) | KDIGO | AKI within 12h of panel measurement |
| Desai et al., 2022 | Hospitalized patients (systematic review) | Beta-2 microglobulin (B2M), IL-18, KIM-1, L-FABP, NGAL, [TIMP-2]*[IGFBP7] | No mention found | Early detection of drug-induced AKI |
| Han et al., 2008 | Acute/chronic kidney disease, pediatric CPB | Urinary MMP-9, NAG, KIM-1 | >50% SCr increase in 48h | Early AKI diagnosis |
| Koyner et al., 2010 | Cardiac surgery (n=123) | Urinary NGAL, CysC, KIM-1, HGF, α-GST | No mention found | Early detection and prognosis of AKI |
| Pan et al., 2022 | Adults >18, mixed settings (n=38,725) | NGAL (urine/serum), KIM-1, L-FABP, IL-18, [TIMP-2]·[IGFBP7] | KDIGO, AKIN, RIFLE | Predictive performance of biomarkers for AKI |
| Nickolas et al., 2012 | ED patients (n=1,635) | Urinary NGAL, KIM-1, L-FABP, IL-18, CysC | No mention found | Diagnostic/prognostic value |
| Dong et al., 2017 | Pediatric cardiac surgery (n=150) | Urinary NGAL, IL-18, L-FABP, KIM-1, [TIMP-2], IGFBP7 | KDIGO (≥50% SCr increase) | Sequential biomarker elevation for AKI |
Effects
Individual Biomarker Performance
| Biomarker | Area Under the Curve (AUC) Range | Sensitivity Range | Specificity Range |
|---|---|---|---|
| [TIMP-2]·[IGFBP7] | 0.70–0.94 | 42–96% | 50–95% |
| NGAL (urine) | 0.62–0.91 | 55–100% | 64–99.5% |
| KIM-1 (urine) | 0.66–0.84 | 75.9–91.6% | 61.8–95.2% |
| Cystatin C (urine/plasma) | 0.68–0.88 | 71–79.3% | 74.2–92% |
| Albumin (urine) | 0.44–0.94 | No mention found | No mention found |
| IL-18 (urine) | 0.72–0.94 | 75–85% | 63–73% |
| Midkine (urine) | 0.88–0.96 | 87–97% | 85–90% |
| Peptide signature (urine) | 0.78–0.79 | No mention found | No mention found |
| Clusterin (urine) | 0.81 | No mention found | No mention found |
| Urine microscopy/sediment | 0.79–0.865 | 6–30% | 91–98.6% |
Combined Biomarker Performance
Several studies reported that combinations of biomarkers outperformed individual markers. Key findings include:
- Dong et al., 2017: Combination of NGAL, IL-18, and [TIMP-2] yielded an AUC of 0.973 at 12 hours post-cardiopulmonary bypass, higher than any single marker.
- Che et al., 2010: Combination of five biomarkers (cystatin C, NGAL, IL-18, retinol-binding protein, NAG) achieved an AUC of 0.98.
- Gupta et al., 2025: Combination of [TIMP-2]·[IGFBP7], NGAL, and cystatin C yielded an AUC of 0.92, improving to 0.94 when clinical risk factors were included.
- Elmedany et al., 2017: Combination of NGAL, KIM-1, and urine sediment yielded an AUC of 0.906.
Timing of Detection and Clinical Context
| Biomarker/Combination | Optimal Detection Window | Clinical Context | Performance Metrics |
|---|---|---|---|
| NGAL (urine) | 2–6 hours post-injury | Pediatric CPB, sepsis, ICU | AUC >0.9 (early), Sensitivity 84–100%, Specificity 80–99.5% |
| [TIMP-2]·[IGFBP7] | 6–12 hours post-injury | ICU, cardiac surgery, ED | AUC 0.70–0.94, Sensitivity 89–96%, Specificity 50–95% |
| KIM-1 (urine) | 12–24 hours post-injury | Drug-induced, contrast nephropathy | AUC 0.66–0.84, Sensitivity 75.9–91.6%, Specificity 61.8–95.2% |
| Multi-marker panels | 6–24 hours post-injury | Cardiac surgery, ICU, diverse AKI | AUC 0.906–0.98 |
| Urine sediment | 2–48 hours post-injury | Cardiac surgery, ICU | AUC 0.79–0.865, Specificity 91–98.6% |
Factors Affecting Biomarker Performance
- Patient population: Performance varied by clinical context, including ICU, surgery, sepsis, drug-induced injury, pediatric, oncology, and neonates.
- Comorbidities: Some markers, such as [TIMP-2]·[IGFBP7], were reported to be robust across comorbidities, while others may be confounded.
- Timing: Early sampling was critical. NGAL typically rose first, followed by [TIMP-2]·[IGFBP7], KIM-1, and others.
- AKI definition: Variability in AKI definitions affected comparability across studies.
- Analytical methods: Differences in assay platforms, normalization, and cutoff values impacted reported performance.
- Clinical variables: Integration with clinical risk factors and scoring systems improved predictive accuracy.
References
- Ravi J. Desai, C. Kazarov, et al. (2022). Kidney Damage and Stress Biomarkers for Early Identification of Drug-Induced Kidney Injury: A Systematic Review. Drug Safety.
- W. Han et al. (2008). Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney International.
- Sarah Jarvis (2011). ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer: is it really useful? Kidney International.
- J. Koyner et al. (2010). Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clinical Journal.
- Heng-Chih Pan et al. (2022). Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis. Critical Care.
- T. Nickolas et al. (2012). Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. Journal of the American College of Cardiology.
- Liqun Dong et al. (2017). Urinary biomarkers of cell cycle arrest are delayed predictors of acute kidney injury after pediatric cardiopulmonary bypass. Pediatric Nephrology.
Andy but not always bounded.